Abstract:Alzheimer's disease (AD) is a devastating disease characterized by synaptic and neuronal loss in the elderly. Compelling evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce synaptic loss in AD. Aβ-induced synaptic dysfunction is dependent on overstimulation of N-methyl-D-aspartate receptors (NMDARs) resulting in aberrant activation of redox-mediated events as well as elevation of cytoplasmic Ca2+, which in turn triggers downstream pathways involving phospho-tau (p-tau), caspases, Cdk5/dynamin-related protein 1 (Drp1), calcineurin/PP2B, PP2A, Gsk-3β, Fyn, cofilin, and CaMKII and causes endocytosis of AMPA receptors (AMPARs) as well as NMDARs. Dysfunction in these pathways leads to mitochondrial dysfunction, bioenergetic compromise and consequent synaptic dysfunction and loss, impaired long-term potentiation (LTP), and cognitive decline. Evidence also suggests that Aβ may, at least in part, mediate these events by causing an aberrant rise in extrasynaptic glutamate levels by inhibiting glutamate uptake or triggering glutamate release from glial cells. Consequent extrasynaptic NMDAR (eNMDAR) overstimulation then results in synaptic dysfunction via the aforementioned pathways. Consistent with this model of Aβ-induced synaptic loss, Aβ synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). PSD-95, an important scaffolding protein that regulates synaptic distribution and activity of both NMDA and AMPA receptors, is also functionally disrupted by Aβ. PSD-95 dysregulation is likely an important intermediate step in the pathological cascade of events caused by Aβ. In summary, Aβ-induced synaptic dysfunction is a complicated process involving multiple pathways, components and biological events, and their underlying mechanisms, albeit as yet incompletely understood, may offer hope for new therapeutic avenues.

Role of APP and Aβ in Synaptic Physiology.

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The Role of APP in Alzheimer’s Disease

Deciphering the Role of APP in Synaptic Function

Role of APP in Neuronal Function

The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease.

Oligomeric Aβ-induced Synaptic Dysfunction in Alzheimer’s Disease

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

Amyolid Precursor Protein Mediates Presynaptic Localization and Activity of the High-Affinity Choline Transporter

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer’s disease

Physiological functions of APP family proteins.

The amyloid precursor protein: beyond amyloid

Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease

Altered synaptic plasticity at hippocampal CA1-CA3 synapses in Alzheimer's disease: integration of amyloid precursor protein intracellular domain and amyloid beta effects into computational models

Physiological Roles of beta-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology

Advances in the β-amyloid precursor protein of Alzheimer's disease

Regulation of Neurotransmitter Release by Amyloid Precursor Protein Through Synapsin Phosphorylation

P1–395: the Function of Amyloid Precursor Protein (APP) in Cholinergic System

Synaptic Activity Reduces Intraneuronal Aβ, Promotes APP Transport to Synapses, and Protects Against Aβ-Related Synaptic Alterations